PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
CONCLUSIONS: The PCR-RDB HPV genotyping test is a cost-effective and beneficial cervical cancer primary screening for hospital-based opportunistic screening.
PMID: 30887754 [PubMed - in process]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Colposcopy | Cytology | Genital Warts | HPV Testing | Human Papillomavirus (HPV) | OBGYN | Pathology | Women